PDCD1 and renal cell adenocarcinoma: Moreover, understanding the RCC microenvironment has opened new therapeutic strategies with immune check point inhibitors as anti- cytotoxic T-Lymphocyte Antigen 4 (anti-CTL4) and anti-programmed cell death-1 (anti-PD-1) monoclonal antibodies [23].